

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-23 (Cancelled).

24 (Currently Amended). An isolated amino-terminally truncated MCP-2 polypeptide consisting of comprising residues 2-76 of an MCP-2 polypeptide according to SEQ ID NO:2, wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residue 1 of SEQ ID NO:2 and has chemokine antagonistic activity.

25 (Currently Amended). An isolated amino-terminally truncated MCP-2 polypeptide consisting of comprising residues 3-76 of an MCP-2 polypeptide according to SEQ ID NO:2, wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-2 of SEQ ID NO:2 and has chemokine antagonistic activity.

26 (Currently Amended). An isolated amino-terminally truncated MCP-2 polypeptide consisting of comprising residues 4-76 of an MCP-2 polypeptide according to MCP-2 (SEQ ID NO: 2), wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-3 of SEQ ID NO:2 and has chemokine antagonistic activity.

27 (Currently Amended). An isolated amino-terminally truncated MCP-2 polypeptide consisting of comprising residues 5-76 of an MCP-2 polypeptide according to SEQ ID NO:2, wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-4 of SEQ ID NO:2 and has chemokine antagonistic activity.

28-30 (Cancelled).

31 (Currently Amended). An isolated amino-terminally truncated MCP-2 polypeptide consisting of comprising residues 6-76 of an MCP-2 polypeptide according to SEQ ID NO:2, wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-5 of SEQ ID NO:2 and has chemokine antagonistic activity.

32 (Currently Amended). The isolated amino-terminally truncated MCP-2 polypeptide of any one of claims 24-27 and 31, wherein the truncated MCP-2 polypeptide is in glycosylated form.

33 (Previously Presented). A pharmaceutical composition comprising an isolated truncated MCP-2 polypeptide according to any one of claims 24-27 and 31, wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.

Appln. No. 09/537,859

Amdt. dated December 23, 2004

Reply to Office action of July 23, 2004

34 (Previously Presented). The pharmaceutical composition according to claim 33, wherein the isolated truncated MCP-2 polypeptide is in glycosylated form.